DOWNLOAD
HCA Healthcare
- Bond: HCA 5.25 30
- Indicative Yield-to-Maturity (YTM): 5.015%
- Credit Rating : BBB
Detailed Information
Fundamental View
AS OF 12 Mar 2025- HCA’s volume metrics and EBITDA margins consistently best industry peers, primarily due to strong operational efficiency and an inpatient/outpatient focus within large, healthy markets.
- HCA’s credit metrics have improved in recent years and leverage sits modestly below the low end of management’s target net leverage range of 3-4x.
- HCA benefits from substantial financial flexibility provided by strong FCF generation and easy access to the capital markets. The company also maintains sufficient liquidity with a well-laddered maturity schedule.
Business Description
AS OF 12 Mar 2025- HCA operates more than 180 hospitals with ~50k beds and 125 freestanding surgery units (as of 3Q24). The company operates in 20 states and England, but ~50% of its hospitals are located in Texas and Florida. HCA is the largest for-profit hospital operator in the US by revenue. HCA also recently purchased 41 urgent care centers in Texas from FastMed for an undisclosed amount.
- HCA has gone private twice since its initial public offering in 1969, most recently in 2006. During periods of private ownership the company has engaged in debt-financed special dividends. HCA returned to public ownership in 2011.
- HCA has been an active consolidator in the industry, acquiring General Health Services, Columbia Healthcare, Hospital Affiliates, and Healthcare Corp, among others. In rationalizing its offering of services and market focus, HCA has sold or spun-off hospital groups such as LifePoint, Triad, and HealthTrust.
Risk & Catalysts
AS OF 12 Mar 2025- We see some risk of choppy operating performance tied to an unwind of acuity and payor mix benefits experienced through COVID.
- HCA guides to FY24 revenue growth of ~9% and adjusted EBITDA growth of ~10%. Management reported an 18% YoY decline in 3Q24 contract labor costs and with expectations of this trend to continue through FY24.
- HCA maintains the flexibility to manage to target leverage levels. Net leverage totaled 2.9x at 3Q24, modestly below management’s 3-4x target range. HCA’s board recently approved a $6 bn share repurchase program, implying $1.7 bn of additional repurchases in 4Q24.
Key Metric
AS OF 19 Dec 2024| $ mn | Y19 | Y20 | Y21 | Y22 | Y23 | LTM 3Q24 |
|---|---|---|---|---|---|---|
| Revenue | 51,336 | 51,533 | 58,752 | 60,233 | 64,968 | 69,621 |
| SWB | 23,560 | 23,874 | 26,779 | 27,685 | 29,487 | 30,823 |
| Supplies | 8,481 | 8,369 | 9,481 | 9,371 | 9,902 | 10,546 |
| Adj. EBITDA | 9,857 | 10,037 | 12,644 | 12,067 | 12,726 | 13,788 |
| Total Debt | 33,722 | 31,004 | 34,579 | 38,084 | 39,593 | 42,965 |
| Gross Leverage | 3.4x | 3.1x | 2.7x | 3.2x | 3.1x | 3.1x |
| Interest Coverage | 5.1x | 6.2x | 8.4x | 7.3x | 6.7x | 7.5x |
Scroll to view columns
CreditSight View Comment
AS OF 24 Jan 2025We maintain an Outperform recommendation on HCA. HCA remains one of the strongest hospital operators in the for-profit space, exhibiting operational stability, strong FCF generation, and a conservative M&A track record. While HCA trades modestly wide to the BBB Index, we see it as a good alternative to some of the widest BBB-rated credits in our IG Pharma universe, namely Biogen and Viatris.
Recommendation Reviewed: January 24, 2025
Recommendation Changed: May 02, 2018
Recommended Issuers
Who We Recommend
SM Investments Corporation
Bond:
SMP 5.375 29
Credit Rating:
Unrated
Mexico
Bond:
Mex 4.125 26
Credit Rating:
BBB
Chile
Bond:
CHILE 3.125 26
Credit Rating:
A
